Company Overview of KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. Its lead product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal, and neurological problems. The company is also developing proprietary monoclonal antibodies, including lenzilumab, which is in Phase I clinical trial in patients with chronic myelomonocytic leukemia; and ifabotuzumab that has completed Phase I/II clinical trial in multiple hematologic malignancies, as well as evaluating further studies of ifabotuzumab in rare solid tumors, such as glioblastoma, oth...
1000 Marina Boulevard
Brisbane, CA 94005
Founded in 2000
Key Executives for KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. does not have any Key Executives recorded.
KaloBios Pharmaceuticals, Inc. Key Developments
KaloBios Pharmaceuticals, Inc. Presents at Second Annual Disruptive Growth and Healthcare Conference, Feb-16-2017 01:15 PM
Feb 12 17
KaloBios Pharmaceuticals, Inc. Presents at Second Annual Disruptive Growth and Healthcare Conference, Feb-16-2017 01:15 PM. Venue: Convene, 730 Third Avenue, New York, New York, United States. Speakers: Cameron Durrant, Chairman of the Board, Chief Executive Officer, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee.
KaloBios Pharmaceuticals, Inc. Presents at 19th Annual BIO CEO & Investor Conference, Feb-13-2017
Jan 30 17
KaloBios Pharmaceuticals, Inc. Presents at 19th Annual BIO CEO & Investor Conference, Feb-13-2017 . Venue: The Waldorf Astoria New York, 301 Park Avenue, New York, NY 10022, United States. Speakers: Cameron Durrant, Chairman of the Board, Chief Executive Officer, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee.
KaloBios Pharmaceuticals, Inc. Enters into Credit and Security Agreement
Dec 23 16
On December 21, 2016, KaloBios Pharmaceuticals, Inc. entered into a Credit and Security Agreement with Black Horse Capital Master Fund Ltd., as administrative agent and lender, Black Horse Capital LP, as a lender, Cheval Holdings Ltd., as a lender and Nomis Bay LTD, as a lender. The Credit Agreement provides for a credit facility in the original principal amount of $3,315,217.00. The Credit Agreement provides that the Term Loan will be made by the Lenders at an original discount equal to $265,217.00 and requires the payment by the Company to the Lenders of a commitment fee equal to $152,500.00. In accordance with the terms of the Credit Agreement, the Company will use the proceeds of the Term Loan for general working capital, the payment of certain fees and expenses owed to the Agent and the Lenders in connection with the Credit Agreement and other costs incurred in the ordinary course of business. Pursuant to the terms of the Credit Agreement, the Term Loan will bear interest at a rate per annum equal to 9.00%. The Term Loan is subject to certain customary representations, warranties and covenants. The outstanding principal balance of the Term Loan, plus accrued and unpaid interest, plus the Commitment Fee and all other non-contingent obligations (the “Outstanding Obligations”), will mature on the earlier of acceleration after an event of default under the Credit Agreement, or October 31, 2017 (the “Maturity Date”). However, to the extent the Company raises capital through any SEC-registered stock offering, 50% of such offering’s proceeds (net of costs) must be used to pay down the Term Loan. Upon the occurrence of any event of default set forth in the Credit Agreement, the Agent has the option of terminating the Credit Agreement and declaring all of the Company’s obligations immediately payable. The occurrence of an event of default will cause the Term Loan to bear interest at a rate per annum equal to 14.00%. The Company’s obligations under the Credit Agreement will be secured by first priority security interests in all of the Company’s real and personal property, subject only to certain carve outs and permitted liens, as set forth in the Credit Agreement. The Company has and will, at the request of the Agent, enter into additional documents further documenting the Term Loan and securing the Company's obligations under the Credit Agreement in favor of the Agent and for the benefit of the Lenders.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 29, 2016
August 29, 2016
June 30, 2016